Business Wire

Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy

Share

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210709005081/en/

With this collaboration, Stallergenes Greer aims to strengthen its precision medicine-based approach and the management of patients with allergies by expanding its knowledge of allergy pathophysiology and endotypes, AIT mode of action and clinical validation.

This research collaboration brings together the longstanding expertise of Stallergenes Greer in AIT and Alyatec’s competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.

“We are excited about the collaboration with Alyatec which will support Stallergenes Greer’s ambition to advance the practice of allergology. With Alyatec and its team of distinguished key opinion leaders, Stallergenes Greer will continue to build on precision medicine and personalised healthcare to significantly improve patient disease outcomes”, declared Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.

This collaboration is a remarkable opportunity for Alyatec to develop precision medicine in AIT. The field of allergology is the oldest form of precision medicine as patient phenotypes are directly related to specific results provided by skin tests. We are convinced that adapting immunotherapy to the phenotype of each patient, in other words finding the right immunotherapy for the right patient, is the future of AIT,” stated Professor Frédéric de Blay, Principal investigator and Medical expert of Alyatec.

ABOUT ALLERGEN IMMUNOTHERAPY

Allergies are the most prevalent and fastest growing chronic disease in the industrialised world, affecting over one billion people worldwide1. Allergen immunotherapy is an allergy treatment designed to alter the natural course of respiratory allergies by treating the underlying cause of the disease. Allergen extracts are modifying disease by inducing tolerance in the immune system2,3.

ABOUT STALLERGENES GREER

Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

ABOUT ALYATEC

Alyatec is a contract research organisation based in Strasbourg University Hospital (France) which performs clinical studies related to respiratory allergies. Thanks to its specific knowledge and medical expertise Alyatec can evaluate the effect of solutions against asthma, rhinitis and conjunctivitis caused by environmental factors such as cat allergens, pollens and house dust mites. To perform these clinical trials, Alyatec has an environmental exposure chamber which enables the assessment of the mode of action of allergy treatment solutions in an innovative and efficient way. The company provides a full range of clinical services in the area of respiratory allergies with all the benefits related to the use of Alyatec’s allergen exposure unit.

1.World Health organisation, Ambient Air Pollution: Health Impacts
2.Global Atlas of Allergy, EAACI 2014
3.Halken 2017: EAACI guidelines on allergen immunotherapy: Prevention of allergy

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stallergenes Greer
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com

Alyatec
Nathalie Domis
Tel: +33(0) 67 68 00 90
Email: Nathalie.Domis@alyatec.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b

The Consortium Welcomes Playtech’s Confirmed Recommendation for Its Binding Agreement to Acquire Finalto and Urges Investors to Vote in Favour at the Playtech Adjourned General Meeting on 18 August 20212.8.2021 19:41:00 CEST | Press release

Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), welcomes the announcement by Playtech plc (“Playtech”) confirming its recommendation that shareholders vote in favour of the Consortium’s binding agreement for Finalto Group (“Finalto) (the “Binding Agreement”). Playtech announced today that following its engagement with Gopher Investments (“Gopher”) over the past three weeks, it has not received responses from Gopher to a number of its questions and therefore “Playtech has not yet been able to achieve the necessary clarity on Gopher's ultimate ownership and funding structure, source of funds or ability to obtain the required regulatory clearances”. Shareholders should ask why Gopher continues to hide and should also be suspicious of Gopher’s credibility, particularly given that disclosure is crucial when buying a highly

Lenovo Climbs 65 Places to Record #159 On ‘FORTUNE Global 500’ List2.8.2021 17:09:00 CEST | Press release

After achieving historical 2021 fiscal year results, Lenovo has been ranked #159 on FORTUNE’s annual Global 500 List and in the top 20 (#15) of all Technology sector companies cited in the List. Lenovo jumped 65 spots this year to an all-time high ranking due to its record financial results, which saw the Group surge past the US$60 billion revenue mark, and adding more than US$10 billion from the previous fiscal year as all core businesses grew. The Fortune Global 500 is the annual ranking of the largest 500 corporations in the world as measured by total revenue. Together, companies on The Global 500 generated US$31.7 trillion in revenue and US$1.6 trillion in profits in 2020, employ 69.7 million people worldwide and are represented by 31 countries. Lenovo’s updated ranking reflects the company’s clear strategy, product innovation, operational excellence, and global/local footprint within the past year. These results reinforced the company’s resilience and ability to achieve balanced,

From Panasonic i-PRO Sensing Solutions to “i-PRO”, Renewing Its Company Name From April 20222.8.2021 17:00:00 CEST | Press release

Panasonic i-PRO Sensing Solutions Co., Ltd. will renew its company name to "i-PRO Co., Ltd." on April 1, 2022. Our company was established in October 2019 as a business separation from Panasonic Corporation, and we have incorporated the network camera brand "i-PRO" into our company name. With the new brand "i-PRO", we have been developing and delivering products that incorporate various innovations to our customers, with "Extend human senses through technology, to capture moments of truth so the front-line professionals can act." as our brand purpose for our existence in society. With our global headquarters located in Japan, we will continue our daily efforts to innovate and develop a range of products under the global brand name "i-PRO", which will be launched in markets around the world. In advance of it, i-PRO EMEA B.V. will be headquartered in Amsterdam and start operations as of October 1st, 2021, in the transition of its European Security and Industrial Medical Vision (IMV) busi

Technology Innovation Institute Appoints Eminent Technologist Dr Ray O. Johnson as CEO2.8.2021 15:54:00 CEST | Press release

Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology body in Abu Dhabi responsible for driving research and development for transformative technology outcomes, today announced the appointment of veteran technologist and entrepreneur Dr Ray O. Johnson as Chief Executive Officer. Dr Johnson will work on shaping the strategic direction of the Institute and lead the execution of its growth strategies to achieve operational excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005462/en/ Dr Ray O. Johnson, Chief Executive Officer, Technology Innovation Institute (Photo: AETOSWire) Prior to joining TII, Dr Johnson was an Operating Partner at Bessemer Venture Partners, a top-tier American venture capital company that has been part of 130 IPOs in the last 50 years, and before that, he was the Corporate Senior Vice Preside

Esri Signs Goodwill Protocol with Atlas University2.8.2021 14:00:00 CEST | Press release

Esri, the global leader in location intelligence, today announced it signed a protocol to extend cooperation with Atlas University in Istanbul, Turkey, through its distributor, Esri Turkey. In doing so, Atlas University seeks to enable students to learn and develop the application of geospatial technology in all their activities. Atlas University was established in 2018, and it aims to use geographic information system (GIS) solutions in its related units, especially in the Faculty of Engineering and Natural Sciences. For this purpose, the Continuous Education Center (AtlasSEM) in the university will also serve as a GIS base. This center will be allocated to provide training on GIS, using Esri technology, and courses will be included in the online training contents offered by AtlasSEM. Additionally, the institution will jointly conduct research and development activities in the field of GIS. Evaluating the protocol, the president of the Board of Trustees of Atlas University, Dr. Yusuf

H.I.G. Capital to Acquire Quick Restaurants S.A.2.8.2021 13:08:00 CEST | Press release

H.I.G. Capital, LLC (“H.I.G.”), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that an affiliate has entered into a definitive agreement to acquire Quick Restaurants S.A. (the “Company” or “Quick”) from Burger King France. The transaction is expected to be completed before the end of the year, following regulatory approval. Established in 1971, Quick is one of the leading burger fast food chains. Present in France since 1980, Quick serves more than 36 million meals per year from a network of 107 restaurants. Olivier Boyadjian, Managing Director at H.I.G. Capital commented, “H.I.G.’s investment will support Quick’s management team in its transition to an independent company and further accelerate its expansion with an objective of doubling the size of its network in the coming years.” About H.I.G. Capital H.I.G. is a leading global private equity and alternative assets investment firm with $45 billion of equity ca

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom